AstraZeneca Collaboration Pays Silence Therapeutics $10 Million Milestone Payment
Silence Therapeutics plc AstraZeneca has nominated the first product candidate under its siRNA (short interfering RNA) collaboration and will pay Silence a $10 million option fee to advance development on an undisclosed program, according to SLN Silence” or “the Company. Silence Therapeutics is creating a new generation of medications by using the body’s natural RNA … Read more